One Incremental Stride for Doxycycline, One Substantial Advancement for Thyroid Eye Disease

Area of Science:

• Ophthalmology
• Endocrinology
• Rheumatology

Background:

• Thyroid eye disease (TED) is an autoimmune condition often linked to thyroid dysfunction.
• Current treatments for TED focus on managing inflammation and its effects on ocular structures.
• Doxycycline, an antibiotic with known anti-inflammatory properties, has not been extensively studied for TED.

Purpose of the Study:

• To evaluate the efficacy of a 12-week doxycycline treatment regimen for patients with thyroid eye disease.
• To assess doxycycline's impact on clinical signs and patient-reported quality of life in TED.

Main Methods:

• A randomized controlled clinical trial involving 82 patients with TED.
• Participants were randomized 1:1 to receive doxycycline (50 mg) or no treatment for 12 weeks.
• Outcome measures included margin reflex distance (MRD), eyelid aperture, proptosis, ocular motility, diplopia, and the Graves' ophthalmopathy-specific quality-of-life (GO-QOL) scale.

Main Results:

• The doxycycline group showed significant improvements in MRD2 and clinical activity score by week 12.
• A notable increase in participants reporting good quality of life was observed in the doxycycline group (51.22% to 70.73%).
• Doxycycline demonstrated anti-inflammatory and immunomodulatory effects relevant to TED management.

Conclusions:

• A 12-week course of doxycycline appears effective in improving clinical outcomes and quality of life for patients with thyroid eye disease.
• Doxycycline's anti-inflammatory and immunomodulatory properties suggest its potential utility in treating TED and other orbital inflammatory conditions.
• Further research with longer follow-up periods and larger patient cohorts is warranted to validate these findings.